Use and Safety of Remdesivir in Kidney Transplant Recipients With COVID-19

被引：26

作者：

Buxeda, Anna ^{[1
]}

Arias-Cabrales, Carlos ^{[1
]}

Perez-Saez, Maria Jose ^{[1
]}

Cacho, Judit ^{[2
]}

Pelegrin, Sheila Cabello ^{[3
]}

Melilli, Edoardo ^{[4
]}

Aladren, Maria Jose ^{[5
]}

Galeano, Cristina ^{[6
]}

Lorenzo, Inmaculada ^{[7
]}

Mazuecos, Auxiliadora ^{[8
]}

Saura, Isabel Maria ^{[9
]}

Franco, Antonio ^{[10
]}

Ruiz-Fuentes, Maria del Carmen ^{[11
]}

Sanchez-Camara, Luis Alberto ^{[12
]}

Siverio, Orlando ^{[13
]}

Martin, Maria Luisa ^{[14
]}

Gonzalez-Garcia, Elena ^{[15
]}

Lopez, Veronica ^{[16
,17
]}

Martin-Moreno, Paloma Leticia ^{[18
]}

Moina, Inigo ^{[19
]}

Berrio, Esperanza Moral ^{[20
]}

Moreso, Francesc ^{[21
]}

Portoles, Jose Maria ^{[22
]}

Santana-Estupinan, Raquel ^{[23
]}

Zarraga, Sofia ^{[24
]}

Canal, Cristina ^{[25
]}

Sanchez-Alvarez, Emilio ^{[26
]}

Pascual, Julio ^{[1
]}

Crespo, Marta ^{[1
]}

机构：

[1] Hosp Mar, Inst Mar Med Res IMIM, Dept Nephrol, Red Invest Renal RED inREN RD16 0009 0013, Barcelona, Spain

[2] Hosp Badalona Germans Trias & Pujol, Dept Nephrol, Barcelona, Spain

[3] Hosp Univ Son Espases, Dept Nephrol, Palma De Mallorca, Spain

[4] Hosp Univ Bellvitge, Dept Nephrol, Barcelona, Spain

[5] Hosp Univ Miguel Servet, Dept Nephrol, Zaragoza, Spain

[6] Hosp Univ Ramon y Cajal, Inst Ramon y Cajal Invest Sanitaria IRYCIS, Dept Nephrol, Madrid, Spain

[7] Hosp Gen Albacete, Dept Nephrol, Albacete, Spain

[8] Hosp Univ Puerta del Mar, Dept Nephrol, Cadiz, Spain

[9] Hosp Univ Virgen de la Arrixaca, Dept Nephrol, Murcia, Spain

[10] Hosp Gen Univ Alicante, Dept Nephrol, Alicante, Spain

[11] Hosp Univ Virgen de las Nieves, Dept Nephrol, Granada, Spain

[12] Hosp Gen Univ Gregorio Maranon, Inst Invest Sanitaria Gregorio Maranon IiSGM, Dept Nephrol, Madrid, Spain

[13] Hosp Univ Nuestra Senora de la Candelaria, Dept Nephrol, Tenerife, Spain

[14] Hosp Arnau Vilanova, Dept Nephrol, Lleida, Spain

[15] Hosp Univ La Paz, Dept Nephrol, Madrid, Spain

[16] Hosp Reg Univ Malaga, Dept Nephrol, Malaga, Spain

[17] Univ Malaga, Inst Invest Biomed Malaga IBIMA, Red Invest Renal REDinREN RD16 0009 0006, Malaga, Spain

[18] Clin Univ Navarra, Navarra Inst Hlth Res IdiSNA, Dept Nephrol, Pamplona, Spain

[19] Hosp Univ Basurto, Dept Nephrol, Bilbao, Spain

[20] Hosp Gen Univ Ciudad Real, Dept Nephrol, Ciudad Real, Spain

[21] Hosp Univ Vall dHebron, Dept Nephrol, Barcelona, Spain

[22] Hosp Univ Puerta de Hierro, Dept Nephrol, Madrid, Spain

[23] Hosp Univ Gran Canaria Doctor Negrin, Dept Nephrol, Las Palmas Gran Canaria, Spain

[24] Hosp Univ Cruces, Dept Nephrol, Bilbao, Spain

[25] Fundacio Puigvert, Dept Nephrol, Barcelona, Spain

[26] Hosp Cabuenes, Dept Nephrol, Gijon, Spain

来源：

KIDNEY INTERNATIONAL REPORTS | 2021年 / 6卷 / 09期

关键词：

acute kidney injury; immunosuppression; kidney transplantation; remdesivir; SARS-CoV2l; MORTALITY; INJURY;

D O I：

10.1016/j.ekir.2021.06.023

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Introduction: Remdesivir has demonstrated antiviral activity against coronavirus, shortening the time to recovery in adults hospitalized with moderate/severe COVID-19. Severe adverse events such as acute kidney injury have been reported. Scant data are available on the use and safety of remdesivir in kidney transplant recipients. Methods: We present a multicenter cohort study of 51 kidney transplant recipients with COVID-19 treated with remdesivir. Outcomes and safety were assessed. Results: Mean age at diagnosis was 60 years, with a median time since kidney transplant of 4.5 years. Mean time since admission to remdesivir was 2 days. Twenty-eight patients (54.9%) required mechanical ventilation (19 noninvasive). Mortality was 18.9% and markedly higher if aged >= 65 years (45% vs. 3.2% in younger patients). Acute kidney injury was present in 27.7% of patients, but was diagnosed in 50% before treatment. No patients required remdesivir discontinuation because of adverse events. We did not find significant hepatoxicity or systemic symptoms resulting from the drug. Conclusion: In our cohort of kidney transplant recipients, remdesivir was well tolerated and safe in renal and hepatic toxicity, but randomized trials are needed to assess its efficacy.

引用

页码：2305 / 2315

页数：11